News >

Frontline Elotuzumab Triplet Misses PFS Endpoint in Multiple Myeloma

Gina Columbus
Published: Monday, Mar 09, 2020

Meletios A. Dimopoulos, MD

Meletios A. Dimopoulos, MD

The addition of elotuzumab (Empliciti) to lenalidomide (Revlimid) and dexamethasone did not show a statistically significant improvement in progression-free survival (PFS) compared with lenalidomide/dexamethasone alone in patients with newly diagnosed, previously untreated, transplant-ineligible multiple myeloma, missing the primary endpoint of the phase III ELOQUENT-1 trial (NCT01335399).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication